Skip to main
STE
STE logo

STERIS (STE) Stock Forecast & Price Target

STERIS (STE) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 25%
Buy 50%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Steris, a global leader in sterilization services and infection prevention, reported a 6.5% organic revenue growth in its healthcare segment, indicating strong demand for its services. The company has updated its fiscal year 2025 revenue guidance to reflect a forecast of 6% organic growth, supported by a notable 9.5% growth in its Applied Sterilization Technologies segment. Despite facing foreign exchange headwinds, Steris remains well-positioned to capitalize on increased healthcare utilization and capital spending in hospitals and life sciences.

Bears say

Steris experienced a slight revenue miss in its 3Q25 results, primarily driven by a 17% year-over-year decline in service revenues and a noteworthy 15% decrease in Capital Equipment sales, indicating potential weaknesses in key business segments. The company's guidance has been adjusted downward, anticipating further challenges in healthcare capital equipment revenues, which are projected to decrease in the coming quarter. Additionally, the resurgence of COVID-19 is expected to adversely impact procedural volumes, further restricting demand for Steris's products and services, compounding integration and geographic risks associated with its acquisitions.

STERIS (STE) has been analyzed by 12 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of STERIS and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About STERIS (STE) Forecast

Analysts have given STERIS (STE) a Buy based on their latest research and market trends.

According to 12 analysts, STERIS (STE) has a Buy consensus rating as of Jul 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $201.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $201.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

STERIS (STE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.